Under the general trend of innovation, how should pharmaceutical companies break the bottleneck of transformation?

In recent years, under the influence of factors such as centralized procurement and the epidemic, China's pharmaceutical industry has begun to face rules and ecological reconstruction
.
It is worth noting that at the same time, in the context of continuous changes in the industry, relevant pharmaceutical companies are also beginning to face greater pressure for transformation
.
In this context, how should pharmaceutical companies choose a suitable pharmaceutical company strategy, make up for shortcomings, and accelerate their own corporate growth? It is understood that foreseeable pharmaceutical companies have already begun to adopt diversified strategic measures to seek transformation and development
.
Currently, there are many types of transformations in the industry.
Transformation and innovation, becoming a generic drug company like Teva, transforming non-medical insurance and general health fields, or becoming a CXO in the pharmaceutical industry chain.
.
.
Among many transformation methods, innovation has become The main direction
.
It is reported that the current leading traditional pharmaceutical companies such as CSPC, Kelun, and Chia Tai Tianqing are all planning to transform the research and development of innovative drugs and high-end generic drugs, and they are accelerating
.
Among them, Hengrui Medicine will cut off all its generic drug research projects in 2019, and only make innovative drugs and high-end generic drugs with core values
.
According to statistics, Hengrui has obtained a total of 82 clinical approvals for innovative drugs in 2020, of which 6 major research projects have entered the phase two-thirds clinical stage
.
At present, Hengrui Pharmaceutical's R&D headquarters project has officially started, and it is expected to accelerate the development of new products, further improve independent R&D capabilities and technological innovation capabilities, and build an innovation system
.
It is worth noting that under the general trend of innovation, the industry has also proposed that the same strategy cannot be used to promote the development of all pharmaceutical companies
.
China's pharmaceutical industry is mainly composed of four types of companies: Biotech, Biopharma, Bigpharma, and Smallpharma, with a complex structure; therefore, different pharmaceutical companies also need to choose appropriate strategies in innovation to fill shortcomings and accelerate growth
.
First of all, a strategic foundation can be built on the basis of survival and sustainable development
.
China's pharmaceutical market has entered from the era of shortage to the era of surplus, and from the era of generic drugs to the era of innovative drugs.
This is a key iterative period for the transformation of the pharmaceutical industry.
It is necessary to grasp the bottom line of operation and the underlying logic layout. .
Secondly, products can be deployed around patients and doctors to cut into unsatisfied needs and markets
.
At the same time, we must be good at cooperation
.
For a long time, Chinese entrepreneurs have been dominated by the thinking of "preferring to be a chicken head rather than a cow queen" and have lost many development opportunities
.
From equity cooperation to product cooperation, from R&D cooperation to terminal cooperation, and from Licensein to Licenseinout, there is more
.
In addition, on the basis of the above three aspects, pharmaceutical companies must be brave and good at cross-industry, integration, innovation, and iteration, break through existing barriers to competition, and achieve leapfrog development
.
It is worth noting that focus, specialization, and differentiation are still the magic weapon for pharmaceutical companies to keep the bottom line
.
Therefore, pharmaceutical companies must adjust their strategies in a timely manner according to the development situation
.
In general, driven by the wave of innovation, local pharmaceutical companies will embark on the path of innovation and transformation
.
However, in this process, pharmaceutical companies need to grasp the direction of national pharmaceutical policies, pay attention to market structure, and prepare in advance or in time
.